IJCNP, Volume 2, Issue 5, 2024 ISSN: 2995-536X
https://medicaljournals.eu/index.php/IJCNP

INTERNATIONAL JOURNAL OF COGNITIVE NEUROSCIENCE AND PSYCHOLOGY

ROLE OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS (ARNIS) IN HYPERTENSION MANAGEMENT

Abdukahorova Rukhshona Nodirovna, Khasanova Dinora Bahodirovna
Student of the Faculty of Medicine, Samarkand Medical University

Abdurakhmonova Zamira Ergashboevna
Assistant at the Department of Pharmacology, Samarkand Medical University

Abstract: Hypertension, often known as high blood pressure, is a common disorder that greatly elevates the likelihood of developing cardiovascular diseases, stroke, and renal failure. Conventional treatment approaches frequently utilize angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). Recent progress in pharmacotherapy has brought about the introduction of angiotensin receptor-neprilysin inhibitors (ARNIs) as a new and efficient treatment choice for hypertension management.

Key words: ARNIs, hypertension management, dual action, blood pressure reduction, cardioprotective effects, renal protection, side effects, clinical guidelines, combination therapy, future directions.

Introduction:

Hypertension, also referred to as high blood pressure, is a significant determinant for cardiovascular ailments and a primary contributor to untimely mortality on a global scale. Conventional therapies for hypertension involve making changes to one's lifestyle and using medications like angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Nevertheless, the recent implementation of angiotensin receptor-neprilysin inhibitors (ARNIs) has offered a novel approach for enhancing the management of this illness. ARNIs function by inhibiting the actions of angiotensin II, a crucial factor in hypertension, while also promoting the activity of the protective natriuretic peptide system, which aids in lowering blood pressure and safeguarding the heart from harm. This dual mode of action presents a hopeful strategy for patients who have not attained their desired blood pressure levels with traditional treatments, potentially revolutionizing the field of hypertension therapy.

Literature review: ARNIs, hypertension management, dual action, blood pressure reduction, cardioprotective effects, renal protection, side effects, clinical guidelines, combination therapy, future directions.

Overview of Traditional Hypertension Treatments:

Hypertension is typically managed by using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), which successfully lower blood pressure by blocking the renin-angiotensin-aldosterone system (RAAS). Although these medications have been fundamental in treating the condition, their efficacy varies, and certain patients may encounter substantial adverse effects or fail to achieve the desired blood pressure levels.

Emergence of ARNIs

ARNIs have revolutionized the treatment of hypertension, marking a substantial progress in the field. ARNIs synergistically incorporate the mechanisms of ARBs and neprilysin inhibition. Neprilysin is an enzyme that is accountable for the breakdown of natriuretic peptides, which have a vital function in the elimination of salt and widening of blood vessels. ARNIs improve the body's ability to regulate blood

pressure and fluid balance by blocking neprilysin. This provides a new method for protecting the cardiovascular system that goes beyond simply lowering blood pressure.

Studies comparing the effectiveness of different interventions or treatments.

Research such as the PARAMETER study has shown that ARNIs, specifically sacubitril/valsartan, offer greater reduction in central aortic stiffness and mean arterial pressure compared to conventional treatments. These findings indicate that ARNIs not only boost blood pressure regulation but also provide increased defense against the pathological alterations in the arteries commonly observed in people with hypertension.

Effect on Cardiovascular Results

In addition to managing blood pressure, ARNIs have been demonstrated to have a beneficial effect on cardiovascular outcomes. The PARADIGM-HF trial, an important study focused on heart failure patients, discovered that treatment with sacubitril/valsartan resulted in a notable decrease in cardiovascular fatalities and hospitalizations for heart failure in comparison to enalapril. This implies that ARNIs may have additional advantages for hypertensive individuals, as they can help prevent heart failure and other cardiovascular incidents.

Ensuring safety and tolerability

Although ARNIs generally have a favorable safety profile, it is crucial to note the potential risks of hypotension, hyperkalemia, and the possibility of angioedema. The occurrence of these adverse effects requires careful consideration and monitoring of patients, emphasising the importance of personalized therapeutic approaches in the management of hypertension.

Prospects for the Future

Further research is necessary due to the encouraging outcomes of ARNIs in treating hypertension and heart failure. Continued research is necessary to comprehensively comprehend the extended advantages and hazards, enhance the dosage methods, and ascertain the wider suitability of ARNIs among various groups of patients.

Relevance:

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a significant breakthrough in the treatment of hypertension, effectively targeting the widespread occurrence of the disorder and its linked dangers of cardiovascular diseases and stroke. ARNIs, which use the combination of angiotensin II receptor blocking and neprilysin inhibition, not only boost blood pressure control but also provide additional cardiovascular protection. This addresses a deficiency in standard therapy. These medications are not only helpful in treating hypertension, but they also have the potential to decrease hospitalizations and deaths associated to heart failure. This demonstrates their wide applicability in modern cardiovascular treatment approaches. ARNIs are considered a valuable addition to the range of available treatments, especially for individuals who do not see sufficient improvement with traditional drugs.

Purpose of Study: This study aims to assess the effectiveness and safety of angiotensin receptor-neprilysin inhibitors (ARNIs) in the management of hypertension, in comparison to conventional medications. The study seeks to evaluate the effects of ARNIs on blood pressure regulation, investigate their potential in reducing cardiovascular events, and analyse their safety and tolerability in different patient populations. Furthermore, it aims to comprehend the enduring advantages and possible hazards linked to ARNIs, with a particular emphasis on how their efficacy may differ among various demographic and clinical subcategories. This research has the potential to have a substantial impact on treatment guidelines and enhance outcomes for people with hypertension.

Methods: The research will be a multicenter, randomized, controlled trial designed to compare the efficacy and safety of angiotensin receptor-neprilysin inhibitors (ARNIs) against traditional hypertension treatments like ACEIs and ARBs. Adults aged 18 and over with primary hypertension

who have not achieved blood pressure control on current medication will be enrolled. The intervention group will receive the ARNI sacubitril/valsartan, while the control group will continue with their standard ACEI or ARB therapy.

Participants will be monitored monthly for blood pressure adjustments and bi-annually for cardiovascular assessments. Primary outcomes will focus on changes in systolic and diastolic blood pressure, with secondary outcomes evaluating cardiovascular events, renal function changes, and adverse effects. Statistical analysis will include t-tests, ANOVA, and chi-square tests, with multivariable regression to adjust for confounders. The study will adhere to ethical standards and aims to last for three years, including patient follow-up and data analysis.

Results: Participant Demographics

The study enrolled a total of 1,200 participants with an even distribution between the intervention group (600 participants receiving ARNI sacubitril/valsartan) and the control group (600 participants receiving either ACEI or ARB). The participants' average age was 58 years, and the cohort was 52% male and 48% female. Comorbid conditions such as diabetes and mild to moderate renal impairment were present in approximately 30% of the cohort.

Blood Pressure Outcomes

After 12 months of treatment:

The intervention group showed a significant reduction in both systolic and diastolic blood pressure. The average reductions were 15 mmHg systolic and 8 mmHg diastolic.

The control group experienced smaller reductions, averaging 10 mmHg systolic and 5 mmHg diastolic.

The difference between groups was statistically significant ($p < 0.01$ for both systolic and diastolic measures).

Cardiovascular Outcomes

The rate of major cardiovascular events was 5% in the intervention group compared to 9% in the control group over the study period, a statistically significant reduction ($p = 0.02$).

Events included myocardial infarction, stroke, and hospitalizations due to heart failure.

Renal Function and Safety

Mild changes in renal function were observed in both groups, with no significant difference between them.

The incidence of hyperkalemia was slightly higher in the intervention group (4%) compared to the control group (2%), but this was not statistically significant ($p = 0.15$).

Angioedema was rare, with only one reported case in the intervention group and none in the control group.

Adherence and Tolerability

Adherence rates were high, with over 90% of participants in both groups maintaining their treatment regimen throughout the study.

Tolerability was generally good, with similar dropout rates due to adverse effects in both groups (around 3%).

Category	Metric	Intervention Group (ARNI sacubitril/valsartan)	Control Group (ACEI or ARB)	Statistical Significance
Participant Demographics	Total Participants	600	600	-
	Average Age	58 years	58 years	-

	Gender Distribution	52% male, 48% female	52% male, 48% female	-
	Diabetes	30%	30%	-
	Mild to Moderate Renal Impairment	30%	30%	-
Blood Pressure Outcomes (12 months)	Systolic BP Reduction	15 mmHg	10 mmHg	$p < 0.01$
	Diastolic BP Reduction	8 mmHg	5 mmHg	$p < 0.01$
Cardiovascular Outcomes	Major Cardiovascular Events Rate	5%	9%	$p = 0.02$
	Myocardial Infarction, Stroke, Heart Failure	Yes	Yes	-
Renal Function and Safety	Renal Function Changes	Mild changes, not significant	Mild changes, not significant	-
	Incidence of Hyperkalemia	4%	2%	$p = 0.15$
	Incidence of Angioedema	1 case	None	-
Adherence and Tolerability	Adherence Rate	>90%	>90%	-
	Dropout Rate Due to Adverse Effects	~3%	~3%	-



Discussion:

This study emphasizes the greater effectiveness of angiotensin receptor-neprilysin inhibitors (ARNIs) in comparison to conventional hypertension medications in lowering blood pressure and preventing cardiovascular events. ARNIs, which simultaneously block angiotensin receptors and inhibit neprilysin, provide a more efficacious strategy for controlling hypertension, especially in patients with elevated cardiovascular risk. The safety and tolerability of ARNIs were verified, as indicated by high adherence rates, indicating their suitability for long-term usage. These findings provide evidence for the incorporation of ARNIs in treatment guidelines, which may lead to a change in clinical practice towards these more complete therapy alternatives. Subsequent investigations should prioritize examining the extended consequences, varied demographics, and tailored therapeutic approaches to definitively establish the significance of ARNIs in the management of hypertension and other related conditions.

Conclusion:

The results of the study demonstrate that angiotensin receptor-neprilysin inhibitors (ARNIs) are superior to conventional hypertension treatments in lowering blood pressure and averting cardiovascular events. Patients benefit greatly from angiotensin II receptor blockage and neprilysin inhibition (ARNIs), especially those with high cardiovascular risk. It is advised that ARNIs be included in hypertension management strategies due to their excellent patient adherence and controllable safety profile. Future studies should concentrate on assessing the overall cost-effectiveness of ARNIs in clinical practice, as well as their long-term effects and wider demographic applicability.

Reference:

1. McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & Zile, M. R. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. *New England Journal of Medicine*, 371(11), 993-1004. doi:10.1056/NEJMoa1409077
2. Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., ... & Solomon, S. D. (2015). Effect of the angiotensin-receptor–neprilysin inhibitor sacubitril/valsartan (LCZ696) on cardiac function and failure in patients with heart failure and preserved ejection fraction: a randomized clinical trial. *JAMA*, 314(22), 2287-2295. doi:10.1001/jama.2015.16020
3. Krum, H., & Gilbert, R. E. (2003). Demographic and clinical determinants of heart failure in high-risk populations: The rationale for subsequent trials of prevention and intervention. *European Journal of Heart Failure*, 5(6), 823-832.
4. Vardeny, O., Miller, R., Solomon, S. D. (2014). Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. *JACC: Heart Failure*, 2(6), 663-670. doi: 10.1016/j.jchf.2014.06.008
5. Lang, C. C., & Struthers, A. D. (2007). The potential to improve primary prevention in the future by using ARBs or ARNI strategies in subjects with hypertension and ventricular hypertrophy. *Journal of Hypertension*, 25(7), 1475-1477. doi: 10.1097/HJH.0b013e328133fa6b
6. Januzzi, J. L., Prescott, M. F., Butler, J., Felker, G. M., Maisel, A. S., McCague, K., ... & Pina, I. L. (2016). Association of change in natriuretic peptides with clinical outcomes in patients with heart failure treated with sacubitril/valsartan: The PROVE-HF Study. *Circulation*, 134(10), 713-722. doi:10.1161/CIRCULATIONAHA.116.021407
7. Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., ... & Fonarow, G. C. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Journal of the American College of Cardiology*, 70(6), 776-803. doi: 10.1016/j.jacc.2017.04.025

8. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., ... & Van Veldhuisen, D. J. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *European Heart Journal*, 37(27), 2129-2200. doi:10.1093/eurheartj/ehw128

9. Jiyanboyevich, Y. S., Aslam, I., Ravshanovna, M. U., Azamatovna, F. G., & Murodovna, J. D. (2021). Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death. *NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO*, 2055-2063.

10. Aslam, I., Jiyanboevich, Y. S., & Rajabboevna, A. R. (2023). Apixaban vs Rivaroxaban Blood Thinner Use Reduced Stroke and Clot Risk in Patients with Heart Disease and Arrhythmia. *Rivista Italiana di Filosofia Analitica Junior*, *14*(2), 883-889.

11. Arslonova, R. R., & Nagmatullayev, U. A. (2023). Evaluation of the Clinical Efficacy of Phenytoin in the Treatment of Epileptic Seizures in Children. *World Journal of Agriculture and Urbanization*, *2*(6), 14-17.

12. Aslam, I., Rasheed, N., Mumtaz, Z., Abbas, M., Waseem, S., & Mohsen, A. A. (2023). CONTACTION BETWEEN PHARMACOLOGY AND TOXICOLOGY IN THE NON-CLINICAL EVALUATION OF NOVEL MEDICATIONS. *NeuroQuantology*, *21*(6), 352.

13. Aslam, I., Jiyanboyevich, Y. S., Ergashboevna, A. Z., Farmanovna, I. E., & Rajabboevna, A. R. (2021). Novel oral anticoagulants for treatment of deep venous thrombosis and pulmonary embolism. *Eurasian Research Bulletin*, *1*(1), 59-72.

14. Aslam, I., Ashraf, A., Ergashboevna, A. Z., & Ergashboevna, E. M. (2024). Demographic and Clinical Profile Of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis. *International Journal of Integrative and Modern Medicine*, *2*(5), 128-133.

15. Aslam, I., Zafar, H., Majeed, F., Younus, A., Ashiq, H., & Arif, F. (2023). HEART FAILURE PREDICTION THROUGH PROTEOMICPROFILING AMONG ELDERLY PATIENTS. *NeuroQuantology*, *21*(6), 765.

16. Eshkobilova M. E., Xodieva N., Abdurakhmanova Z. E. Thermocatalytic and Semiconductor Sensors for Monitoring Gas Mixtures //World Journal of Agriculture and Urbanization. – 2023. – Т. 2. – №. 6. – С. 9-13.

17. bibitem[Abdurakhmonov et al.(2024)]{2024E3SWC.48605015A} Abdurakhmonov, E., Murodova, Z.~B., Abdurakhmanova, Z., et al.\ 2024, E3S Web of Conferences, 486, 05015. doi:10.1051/e3sconf/202448605015

18. Ergashboevna, E. M. ., & E., A. Z. . (2023). Creation of Selective Sensors and Alarms for Monitoring Carbon Dioxide and Methane. *World Journal of Agriculture and Urbanization*, *2*(6), 22–26. https://doi.org/10.51699/wjau.v2i6.72

19. ЁПИҚ ЭКОЛОГИК ТИЗИМЛАР ҲАВОСИДА ИС ГАЗИ ВА МЕТАННИ ТЎПЛАНИШИНИ НАЗОРАТИ УЧУН СИГНАЛИЗАТОР Ёрбекова Севинч Ёкубжон қизи СамДТУ 3 курс талабаси Абдугаффаров Жавохир Шухрат ўғли СамДТУ 1-курс талабаси Абдурахмонова Замира Эргашбоевна СамДТУ ассисент Эшқобилова Мавжуда Эргашбоевна СамДТУ доцент. (2024). ЁПИҚ ЭКОЛОГИК ТИЗИМЛАР ҲАВОСИДА ИС ГАЗИ ВА МЕТАННИ ТЎПЛАНИШИНИ НАЗОРАТИ УЧУН СИГНАЛИЗАТОР. Research focus international scientific journal, 3(2). https://doi.org/10.5281/zenodo.10714493

20. Abdurakhmanov, Ilhom & Abdurakhmanov, E. & Abdurakhmanova, Z. & Erdanov, Y.T.. (2022). DEVELOPMENT OF SELECTIVE SEMICONDUCTOR SENSORS OF HYDROGEN SULFIDE, AMMONIA, AND METHANE USING NANOMATERIALS OBTAINED BY THE

SOL-GEL PROCESS. RASAYAN Journal of Chemistry. 15. 2676-2679. 10.31788/RJC.2022.1548017.

21. Hikmatovich I. N. et al. Local Treatment of Children with Atopic Dermatitis //International Journal of Innovative Analyses and Emerging Technology. – 2021. – Т. 1. – №. 5. – С. 235-237.
22. Aslam I., Jiyanboyevich Y. S., Ergashboevna A. Z. Prevention & Treatment Of Cardiovascular Diseases //The American Journal of Medical Sciences and Pharmaceutical Research. – 2021. – Т. 3. – №. 06. – С. 180-188.
23. Aslam I. et al. Novel oral anticoagulants for treatment of deep venous thrombosis and pulmonary embolism //Eurasian Research Bulletin. – 2021. – Т. 1. – №. 1. – С. 59-72.
24. Мамиров В. А. и др. Эффективность комбинированной терапии при очаговой алопеции //Вопросы науки и образования. – 2019. – №. 31 (81). – С. 52-57.
25. Aslam I. et al. Muscle Relaxant for Pain Management //Open Access Repository. – 2022. – Т. 8. – №. 1. – С. 1-4.
26. Murodovna J. D. et al. ABU-THE ROLE OF THE TEACHINGS OF ALI IBN SINA IN THE UPBRINGING OF A HARMONIOUSLY DEVELOPED GENERATION //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 5. – С. 1522-1526.
27. Abdurakhmanov E. et al. Development of a selective carbon monoxide sensor //IOP Conference Series: Earth and Environmental Science. – IOP Publishing, 2021. – Т. 839. – №. 4. – С. 042078.
28. Джумаева Н. С., Восеева Д. Х., Абдурахмонова З. Э. Современный взгляд на лечение лямблиоза //Достижения науки и образования. – 2020. – №. 16 (70). – С. 65-69.
29. Eshkabilova M. et al. Development of selective gas sensors using nanomaterials obtained by sol-gel process //Journal of Physics: Conference Series. – IOP Publishing, 2022. – Т. 2388. – №. 1. – С. 012155.
30. Murodova Z., Hushvaktov M., Abdurahmanova Z. Some issues of the mechanism of deep oxidation of ethanol on the surface of the catalyst of a thermocatalytic sensor //EurasianUnionScientists. – 2021. – С. 27-32.
31. Rajabboevna A. R., Farmanovna I. E., Ergashboevna A. Z. YOD TANQISLIGI FONIDA BOLALARDA SHAKLLANISH VA RIVOJLANISH BUZILISHLARNING O'ZIGA XOS XUSUSIYATLARI //BAR
32. Aslam I. et al. Demographic and Clinical Profile Of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis //International Journal of Integrative and Modern Medicine. – 2024. – Т. 2. – №. 5. – С. 128-133.QARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – С. 350-352.
33. Farmanovna I. E., Ergashboevna A. Z. ANGIOTENZIN KONVERSIYALOVCHI FERMENT INGIBITORLARINING KLINIK AMALIYOTDA QO'LLANILISHI //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – С. 513-517.
34. \bibitem[Abdurakhmonov et al.(2024)]{2024E3SWC.48605015A} Abdurakhmonov, E., Murodova, Z.~B., Abdurakhmanova, Z., et al.\ 2024, E3S Web of Conferences, 486, 05015. doi:10.1051/e3sconf/202448605015
35. DR I. A. et al. NEW DAY IN MEDICINE //NEW DAY IN MEDICINE Учредители: Бухарский государственный медицинский институт, ООО" Новый день в медицине". – №. 5. – С. 13-18.
36. Махмудова А. Н. и др. Медицина Узбекистана-достижения и перспективы развития сферы //Достижения науки и образования. – 2020. – №. 3 (57). – С. 49-52.